19Nov/13

Remission reinduction with rituximab a possibility for ANCA-associated vasculitis – Skin and Allergy News Digital Network

Remission reinduction with rituximab a possibility for ANCA-associated vasculitis
Skin and Allergy News Digital Network
SAN DIEGO – Retreatment of granulomatosis with polyangiitis or microscopic polyangiitis with rituximab may be safe and effective in reinducing remission, a prospective trial has shown. “The vast majority of patients with ANCA [antineutrophil

19Nov/13

Long-Lasting Gene Therapy Benefits Advanced Heart Failure Patients – Science Daily (press release)

Long-Lasting Gene Therapy Benefits Advanced Heart Failure Patients
Science Daily (press release)
19, 2013 — Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the 

and more »

19Nov/13

Janssen Oncology Data to be Presented at 2013 American Society of … – Business Wire (press release)

Janssen Oncology Data to be Presented at 2013 American Society of
Business Wire (press release)
Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852).

and more »

19Nov/13

Heart failure patients receiving LVAD benefit from injection of millions of … – News-Medical.net


Science Codex

Heart failure patients receiving LVAD benefit from injection of millions of
News-Medical.net
A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular
Mesoblast’s Cell Therapy Strengthens Native Heart Function In Patients With GlobeNewswire (press release)

all 16 news articles »